新华制药富马酸伏诺拉生化学原料药上市申请获批

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorelin, which is primarily used for gastroesophageal reflux disease and is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 1 - The approval of fumaric acid volnorelin will enhance the company's product line [1] - This new product is expected to improve the company's overall competitiveness in the pharmaceutical market [1]